secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIODESIX INC (BDSX)
CIK:        0001439725
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0000950170-25-070292
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biodesix Q1 revenue $18M (+21% YoY); revises FY2025 guidance to $80-85M
-----------------------------------------------------------------------

- Total Q1 2025 revenue $18.0M (+21% YoY); diagnostic testing $16.3M (+18%), development services $1.7M (+61%).
- Gross margin 79.4% (vs 78.6%); net loss $11.1M (improved 18% YoY); Adjusted EBITDA loss $6.2M (improved 11%).
- FY2025 revenue guidance revised to $80-85M due to ~1-quarter delay in sales expansion; still expects Q4 2025 Adj. EBITDA positivity.
- Drew $10M Tranche C from Perceptive Advisors loan, pro forma cash $27.6M; warrants exercise price modified to $0.4191/share.
- Operating expenses $23.4M (+3% YoY): R&D up $0.9M, SG&A down 1%; non-cash stock comp fell to $1.0M from $2.6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439725/000095017025070292/0000950170-25-070292-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439725/000095017025070292/bdsx-20250513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-070292

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer